Protective immunity using MPL-A and autoclaved Leishmania donovani as adjuvants along with a cocktail vaccine in murine model of visceral leishmaniasis

Journal of Parasitic Diseases

Volumn 37, Issue 2, 2013, Pages 231-239

  Kaur, Tejinder ^a   Thakur, Ankita ^a   Kaur, Sukhbir ^a  

^a PANJAB UNIVERSITY   (India)

Author keywords

ALD; gp63; Hsp70; MPL A; Vaccine; Visceral leishmaniasis

Indexed keywords

GAMMA INTERFERON; HEAT SHOCK PROTEIN 70; IMMUNOGLOBULIN G1; IMMUNOGLOBULIN G2A; INTERLEUKIN 10; INTERLEUKIN 2; LEISHMANIA VACCINE; PHOSPHORYL LIPID A; PROTEIN GP63; UNCLASSIFIED DRUG;

ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ANTIBODY RESPONSE; ARTICLE; CELLULAR IMMUNITY; CONTROLLED STUDY; DELAYED HYPERSENSITIVITY; DRUG EFFICACY; FEMALE; INFECTION CONTROL; INFECTION PREVENTION; LEISHMANIA DONOVANI; MALE; MOUSE; NONHUMAN; PARASITE IMMUNITY; PARASITE LOAD; PRIORITY JOURNAL; PROMASTIGOTE; VISCERAL LEISHMANIASIS;

EID: 84885384014     PISSN: 09717196     EISSN: 09750703     Source Type: Journal    
DOI: 10.1007/s12639-012-0171-7     Document Type: Article

References (49)

1. Ashford RW, Desjeux P, Deraadt P (1992) Estimation of population at risk of infection and number of cases of Leishmaniasis. Parasitol Today 8: 104-105.
2. Banuls AL, Hide M, Prugnolle F (2007) Leishmania and the leishmaniases: a parasite genetic update and advances in taxonomy, epidemiology and pathogenicity in humans. Adv Parasitol 64: 1-109.
3. Berberich C, Ramirez-Pineda JR, Hambrecht C, Alber G, Skeiky YA, Moll H (2003) Dendritic cell (DC)-based protection against an intracellular pathogen is dependent upon DC-derived IL-12 and can be induced by molecularly defined antigens. J Immunol 170: 3171-3179.
4. Black CA (1999) Delayed-type hypersensitivity: current theories with an historic perspective. Dermatol Online J 5: 7.
5. Bradley DJ, Kirkley J (1977) Regulation of Leishmania populations within host I. the variable course of Leishmania donovani infections in mice. Clin Exp Immunol 30: 119-129.
6. Carrillo E, Moreno J (2009) Cytokine profiles in canine visceral leishmaniasis. Vet Immunol Immunopathol 128: 67-70.
7. Carvalho EM, Bacellar O, Barral A, Badaro R, Johnson WD Jr (1989) Antigen-specific immunosuppression in visceral leishmaniasis is cell mediated. J Clin Investig 83: 860-864.
8. Carvalho EM, Bacellar O, Brownell C, Regis T, Coffman R, Reed SG (1994) Restoration of IFN-gamma production and lymphocyte proliferation in visceral leishmaniasis. J Immunol 152: 5949-5956.
9. + T cells. Infect Immun 75: 4648-4654.
10. Dube A, Sharma P, Srivastava JK, Misra A, Naik S, Katiyar JC (1998) Vaccination of langur monkeys (Presbytis entellus) against Leishmania donovani with autoclaved L. major plus BCG. Parasitology 116: 219-221.
11. Evans JT, Cluff CW, Johnson DA, Lacy MJ, Persing DH, Baldridge JR (2003) Enhancement of antigen-specific immunity via the TLR4 ligands MPL adjuvant and Ribi. 529. Exp Rev Vaccines 2: 219-229.
12. Ghalib HW, Piuvezam MR, Skeiky YA, Siddig M, Hashim FA, El-Hassan AM, Russo DM, Reed SG (1993) Interleukin 10 production correlates with pathology in human Leishmania donovani infections. J Clin Investig 92: 324-329.
13. Gicheru MM, Olobo JO, Anjili CO, Orago AS, Modabber F, Scott P (2001) Vervet monkeys vaccinated with killed Leishmania major parasites and Interleukin-12 develop a type 1 immune response but are not protected against challenge infection. Infect Immun 69: 245-251.
14. Halle M, Gomez MA, Stuible M, Shimizu H, McMaster WR, Olivier M, Tremblay ML (2009) The Leishmania surface protease GP63 cleaves multiple intracellular proteins and actively participates in p38 mitogen-activated protein kinase inactivation. J Biol Chem 284: 6893-6908.
15. Handman E (2001) Leishmaniasis: current status of vaccine development. Clin Microbiol Rev 14: 229-243.
16. Handman E, Button LL, McMaster RW (1990) Leishmania major: production of recombinant gp63, its antigenicity and immunogenicity in mice. Exp Parasitol 70: 427-435.
17. Heinzel FP, Sadick MD, Holaday BJ, Coffman RL, Locksley RM (1989) Reciprocal expression of interferon gamma or interleukin 4 during the resolution or progression of murine leishmaniasis: evidence for expansion of distinct helper T cell subsets. J Exp Med 169: 59-72.
18. Jaafari MR, Ghafarian A, Farrokh-Gisour A, Samiei A, Kheiri MT, Mahboudi F, Barkhordari F, Khamesipour A, McMaster WR (2006) Immune response and protection assay of recombinant major surface glycoprotein of Leishmania (rgp63) reconstituted with liposomes in BALB/c mice. Vaccine 24: 5708-5717.
19. + Th1/Th2 type of immune response in murine visceral leishmaniasis. Parasitol Res 103: 1413-1419.
20. Kaur J, Kaur T, Kaur S (2011a) Studies on the protective efficacy and immunogenicity of Hsp70 and Hsp83 based vaccine formulations in Leishmania donovani infected BALB/c mice. Acta Trop 119: 50-56.
21. Kaur T, Sobti RC, Kaur S (2011b) Cocktail of gp63 and Hsp70 induces protection against L. donovani in BALB/c mice. Parasite Immunol 33: 95-103.
22. Khalil EAG, El Hassan AM, Zijlstra EE, Mukhtar MM, Ghalib HW, Musa B, Ibrahim ME, Kamil AA, Elsheikh M, Babiker A, Modabber F (2000) Autoclaved Leishmania major vaccine for prevention of visceral leishmaniasis: a randomised, double-blind, BCG-controlled trial in Sudan. Lancet 356: 1565-1569.
23. Laemmli UK (1970) Cleavage of structural proteins during the assembly of the head of bacteriophage T4. Nature 227: 680-685.
24. Lowry OH, Rosebrough NJ, Farr AL, Randal RJ (1951) Protein measurement with the Folin phenol reagent. J Biol Chem 193: 265-275.
25. MacFarlane J, Blaxter ML, Bishop RP, Miles MA, Kelly JM (1990) Identification and characterisation of a Leishmania donovani antigen belonging to the 70-kDa heat-shock protein family. Eur J Biochem 190: 377-384.
26. Michel MY, Fathy FM, Hegazy EH, Hussein ED, Eissa MM, Said DE (2006) The adjuvant effects of IL-12 and BCG on autoclaved Leishmania major vaccine in experimental cutaneous leishmaniasis. J Egypt Soc Parasitol 36: 159-176.
27. Miret J, Nascimento E, Sampaio W, Franca JC, Fujiwara RT, Vale A, Dias ES, Vieira E, da Costa RT, Mayrink W, Campos-Neto A, Reed S (2008) Evaluation of an immunochemotherapeutic protocol constituted of N-methyl meglumine antimoniate (Glucantime) and the recombinant Leish-110f+MPL-SE vaccine to treat canine visceral leishmaniasis. Vaccine 26: 1585-1594.
28. Misra A, Dube A, Srivastava B, Sharma P, Srivastava JK, Katiyar JC, Naik S (2001) Successful vaccination against Leishmania donovani infection in Indian langur using alum-precipitated autoclaved Leishmania major with BCG. Vaccine 19: 3485-3492.
29. Moreno J, Nieto J, Masina S, Canavate C, Cruz I, Chicharro C, Carrillo E, Napp S, Reymond C, Kaye PM, Smith DF, Fasel N, Alvar J (2007) Immunization with H1, HASPB1 and MML Leishmania proteins in a vaccine trial against experimental canine leishmaniasis. Vaccine 25: 5290-5300.
30. Murphy ML, Wille U, Villegas EN, Hunter CA, Farrell JP (2001) IL-10 mediates susceptibility to Leishmania donovani infection. Eur J Immunol 31: 2848-2856.
31. Nagill R, Kaur S (2010) Enhanced efficacy and immunogenicity of 78 kDa antigen formulated in various adjuvants against murine visceral leishmaniasis. Vaccine 28: 4002-4012.
32. Nagill R, Mahajan R, Sharma S, Kaur S (2009) Induction of cellular and humoral responses by autoclaved and heat-killed antigen of Leishmania donovani in experimental visceral leishmaniasis. Parasitol Int 58: 359-366.
33. Nascimento E, Mayrink W, da Costa CA, Michalick MS, Melo MN, Barros GC, Dias M, Antunes CM, Lima MS, Taboada DC (1990) Vaccination of humans against cutaneous leishmaniasis: cellular and humoral immune responses. Infect Immun 58: 2198-2203.
34. Nylen S, Maasho K, Soderstrom K, Ilg T, Akuffo H (2003) Live Leishmania promastigotes can directly activate primary human natural killer cells to produce interferon-gamma. Clin Exp Immunol 131: 457-467.
35. Olobo JO, Anjili CO, Gichero MM, Mbati PA, Kariuki TM, Githure JI, Koech DE, McMaster WR (1995) Vaccination of vervet monkeys against cutaneous leishmaniosis using recombinant Leishmania major surface glycoprotein (gp63). Vet Parasitol 60: 199-212.
36. Pearson RD, Wheeler DA, Harrison LH, Kay HD (1983) The immunobiology of leishmaniasis. Rev Infect Dis 5: 907-926.
37. Rafati S, Gholami E, Hassani N, Ghaemimanesh F, Taslimi Y, Taheri T, Soong L (2007) Leishmania major heat shock protein 70 (Hsp70) is not protective in murine models of cutaneous leishmaniasis and stimulates strong humoral responses in cutaneous and visceral leishmaniasis patients. Vaccine 25: 4159-4169.
38. Requena JM, Iborra S, Carrion J, Alonso C, Soto M (2004) Recent advances in vaccines for leishmaniasis. Exp Opin Biol Ther 4: 1505-1517.
39. Sachdeva R, Banerjea AC, Malla N, Dubey ML (2009) Immunogenicity and efficacy of single antigen gp63, polytope and polytope Hsp70 DNA vaccines against visceral leishmaniasis in experimental mouse model. PLoS ONE. doi: 10. 1371/journal. pone. 0007880.
40. Seder RA, Germain RN, Linsley PS, Paul WE (1994) CD28-mediated costimulation of interleukin 2 (IL-2) production plays a critical role in T cell priming for IL-4 and interferon gamma production. J Exp Med 179: 299-304.
41. Singh S, Sivakumar R (2004) A gp63 based vaccine candidate against visceral leishmaniasis. J Infect Chemother 10: 307-315.
42. Sinha S, Sundaram S, Singh AP, Tripathi A (2011) A gp63 based vaccine candidate against visceral leishmaniasis. Bioinformation 5: 320-325.
43. Skeiky YA, Benson DR, Guderian JA, Whittle JA, Bacelar O, Carvalho EM, Reed SG (1995) Immune responses of leishmaniasis patients to heat shock proteins of Leishmania species and humans. Infect Immun 63: 4105-4114.
44. Squires KE, Schreiber RD, McElrath MJ, Rubin BY, Anderson SL, Murray HW (1989) Experimental visceral leishmaniasis: role of endogenous IFN-gamma in host defense and tissue granulomatous response. J Immunol 143: 4244-4249.
45. Srivastava JK, Misra A, Sharma P, Srivastava B, Naik S, Dube A (2003) Prophylactic potential of autoclaved Leishmania donovani with BCG against experimental visceral leishmaniasis. Parasitology 127: 107-114.
46. Sukumaran B, Madhubala R (2004) Leishmaniasis: current status of vaccine development. Curr Mol Med 4: 667-669.
47. Trigo J, Abbehusen M, Netto EM, Nakatani M, Pedral-Sampaio G, de Jesus RS, Goto Y, Guderian J, Howard RF, Reed SG (2010) Treatment of canine visceral leishmaniasis by the vaccine Leish-111f+MPL-SE. Vaccine 28: 3333-3340.
48. Tripathi P, Singh V, Naik S (2007) Immune response to Leishmania: paradox rather than paradigm. FEMS Immunol Med Microbiol 51: 229-242.
49. Yardley V, Khan AA, Martin MB, Slifer TR, Araujo FG, Moreno SN, Docampo R, Croft SL, Oldfield E (2002) In vivo activities of farnesyl pyrophosphate synthase inhibitors against Leishmaniadonovani and Toxoplama gondii. Antimicrob Agents Chemother 46: 929-931.